DDInter1285 DDInter899
A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Nevirapine {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
Nevirapine {u} (Compound) binds {v} (Gene) CYP3A5
Nevirapine {u} (Compound) is included by {v} (Pharmacologic Class) Non-Nucleoside Reverse Transcriptase Inhibitors
Nevirapine {u} (Compound) causes {v} (Side Effect) Hypersensitive syndrome
Nevirapine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Prasugrel
Nevirapine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Nevirapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cisapride
Nevirapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pegaspargase
Nevirapine {u} may lead to a major life threatening interaction when taken with {v} Brigatinib
Nevirapine (Compound) treats acquired immunodeficiency syndrome (Disease)
Nevirapine (Compound) binds CYP3A5 (Gene)
Nevirapine (Compound) is included by Non-Nucleoside Reverse Transcriptase Inhibitors (Pharmacologic Class)
Nevirapine (Compound) causes Hypersensitive syndrome (Side Effect)
Nevirapine may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Nevirapine may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Cisapride
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase
Nevirapine may lead to a major life threatening interaction when taken with Brigatinib